Chiron begins review as vaccine wrangle persists
Biotech company Chiron is reviewing its UK public affairs and PR accounts as it deals with the fallout from the suspension of its flu vaccine facility in Liverpool.
Sign in to continue
Need to activate your subscription?
Domain/Group Subscriptions
Click here >>
Individual Subscriptions
Click here >>
Need to activate your Subscription
Company Wide Subscriptions
Click here >>
UK Individual Subscribers
Click here >>